European Federation for Medicinal Chemistry

Best Practices for Proteolysis Targeting Chimeras PROTACs

Best Practices for PROTACs - Development of PROTACs as Drugs (Part 1C)

Best Practices for PROTACs - Assays and Cooperativity (Part 1B)

Best Practices for PROTACs - UPS, MoA and Design of PROTACs (Part 1A)

Best Practices for Hit-to-Lead - Case Study: MALT1 Inhibitors

Best Practices in Hit to Lead - Webinar (Part 2)

Best Practices in Hit to Lead - Webinar (Part 1)

EFMC & EFMC-YSN celebrate the International Day for Women and Girls in Science.

Best Practices for Hit-to-Lead - Case Study: HSD17B13

Hit Generation: Case Study - Factor D Hit Generation

Hit Generation - Webinar (Part Seven: Integrated Hit Generation Strategies)

Hit Generation - Webinar (Part Six: DNA Encoded Libraries and Evolutionary Techniques)

Hit Generation - Webinar (Part Five: Novel Screening Strategies - Fragment Based Screening)

Hit Generation - Webinar (Part Four: Classical Screening Strategies - Screening Technologies)

Hit Generation - Webinar (Part Three: Classical Screening Strategies - Hit Validation)

Hit Generation - Webinar (Part Two: Classical Screening Strategies - Screening Approaches)

Hit Generation - Webinar (Part One: Introduction to Hit Generation)

Is There a Rule of Thumb for Selecting Chemical Probes? - Round Table

Sympathy for the Methyl - Prof. Gianluca Sbardella (University of Salerno, ITALY)

Innovation in Precision Chemistry for Identification of Novel Chemical Probes - Dr Ton VRIES Symeres

opnMe.com: the Boehringer Ingelheim´s Open Innovation Portal -Dr Florian MONTEL Boehringer Ingelheim

Challenges and Opportunities in PROTAC vs Small Molecules Development - Round Table discussion

Controlling Physicochemical Properties in Drug Design - Dr Klemens Hoegenauer (Novartis, CH)

Precision Chemistry applied to PROTACs - Dr Luc Van Hijfte (Symeres, NL)

Gender Balance in Medicinal Chemistry: How can we do better? - Round Table Discussion

Women in Medicinal Chemistry: Per Aspera Ad Astra - Prof. Maria Laura Bolognesi - UniBo

Phenotypic Drug Discovery - Webinar (Part Two)

Phenotypic Drug Discovery: Case Study - Identifying New Druggable Targets in the Wnt-pathway

Phenotypic Drug Discovery - Webinar (Part One)

Phenotypic Drug Discovery : Case Study - Identifying Treatments for Spinal Muscular Atrophy (SMA)